Is Bolt Biotherapeutics, Inc. (BOLT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 305.4% / 30% | 573.4% / 30% | 14.1% / 30% | 68.34% / 5% | ✗ NOT HALAL |
| DJIM | 305.4% / 33% | 573.4% / 33% | 14.1% / 33% | 68.34% / 5% | ✗ NOT HALAL |
| MSCI | 25.3% / 33% | 47.5% / 33% | 1.2% / 33% | 68.34% / 5% | ✗ NOT HALAL |
| S&P | 305.4% / 33% | 573.4% / 33% | 14.1% / 33% | 68.34% / 5% | ✗ NOT HALAL |
| FTSE | 25.3% / 33% | 47.5% / 33% | 1.2% / 50% | 68.34% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -270.8% | |
| Operating Margin | -224.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -79.7% | |
| Return on Assets (ROA) | -27.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$40M |
| Free Cash Flow | -$40M |
| Total Debt | $23M |
| Debt-to-Equity | 86.6 |
| Current Ratio | 3.6 |
| Total Assets | $57M |
Price & Trading
| Last Close | $4.50 |
| 50-Day MA | $5.12 |
| 200-Day MA | $5.42 |
| Avg Volume | 26K |
| Beta | 0.9 |
|
52-Week Range
$3.91
| |
About Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Bolt Biotherapeutics, Inc. (BOLT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Bolt Biotherapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Bolt Biotherapeutics, Inc.'s debt ratio?
Bolt Biotherapeutics, Inc.'s debt ratio is 305.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 25.3%.
What are Bolt Biotherapeutics, Inc.'s key financial metrics?
Bolt Biotherapeutics, Inc. has a market capitalization of $8M, and revenue of $8M. Return on equity stands at -79.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.